Agendia Level 1B Evidence Shows MammaPrint® is the First and Only FDA-cleared Gene Expression Profiling Test to Predict Benefit from Extended Endocrine Therapy in Early-Stage Breast Cancer Patients

 

Tech Analyst: Decision Intelligence Delivers Unparalleled Value to Organizations

 

Fraud Rings Continue to Rise as Cybercriminals Adopt 24/7 Global Attack Model, Reveals Onfido's 2023 Fraud Report

 

ONWARD Reports Interim Clinical Outcomes for Implantable ARC Therapy Demonstrating Potential to Improve Blood Pressure Regulation after Spinal Cord Injury

 

OCI N.V. Breaks Ground on 1.1 mtpa Blue Ammonia Site in Texas, USA

 

Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia’s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy

 

MotorK: Transaction in Own Shares

 

Agendia Spotlights the Future of Personalized Breast Cancer Care at 2022 San Antonio Breast Cancer Symposium

 

AM Best Affirms Credit Ratings of Nova Casiopea Re S.A.

 

AM Best Upgrades Credit Ratings of S2C S.p.A. Compagnia di Assicurazioni di Crediti e Cauzioni